...进展生存期（progression free survival，PFS）是指自化疗开始至出现疾病进展时间或末次随访时间。总生存率（overall survival，OS）是指自化疗开始至死亡时间或末次随访时间。根据NCI-CTC 2.0或NCI-CTC 3.0评价化疗不良反应。
基于222个网页-相关网页
overall survival rate 总生存率 ; 总体生存率 ; 年总生存率
median overall survival 平均总生存时间 ; 生存期
overall survival OS 总生存期
overall survival time 时间 ; 总生存时间
overall survival after hepaticmetastasis 期及出现肝转移后生存
os overall survival 总生存率
OS-Overall Survival 总生存期
overall survival e 总生存率
The 3-year overall survival rate was 66.7%.
3年总生存率是66.7%。
参考来源 - 三阴性乳腺癌的临床病理特点及预后因素分析However, cisplatin-based therapy showed a trend to benefit in TP53 wild type and to be harmful in TP53 mutated patients (P =0.18 for Overall Survival (OS) and P =0.13 for Disease Free Survival (DFS).
但是,存在一种趋势:顺铂辅助化疗有利于TP53野生型患者的生存,而有害于TP53突变型患者的生存(P=0.18总生存期和P=0.13无病生存期)。
参考来源 - TP53、KRAS和EGFR基因在非小细胞肺癌顺铂辅助化疗中肿瘤标记物的研究In the multivariate analysis,cytology classification, histological type were prognostic factors for local relap se and cervical invasion was prognostic factor for overall survival.
Cox多变量回归分析显示,细胞学分级、组织学类型与子宫内膜癌的复发有关,宫颈是否侵犯与总体存活有关。
参考来源 - 112例子宫内膜癌临床特点及预后因素分析·2,447,543篇论文数据，部分数据来源于NoteExpress
The overall survival curves of the 2 cohorts were superimposable, the researchers commented.
研究人员评论说，这两个队列的总体生存曲线是可叠加的。
Obviously, the most important endpoint is overall survival.
显然，最重要的终点是总体生存率。
Overall survival after two years was similar among both groups—88% on the drug versus 80% on placebo.
但是两组患者两年后的总存活率相似，服药组为88％，服用安慰剂组为80％。
"Women who had their ovaries removed had a decrease in the risk of breast cancer, a decrease in the risk of ovarian cancer and,in addition,they were less likely to die of breast cancer, less likely to die of ovarian cancer and also had an improvement in their overall survival."
VOA: special.2010.09.22
应用推荐